{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:45:15Z","timestamp":1793144715459,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hepatitis B virus (HBV) epidemiology in Europe differs by region and population risk group, and data are often incomplete. We estimated chronic HBV prevalence as measured by surface antigen (HBsAg) among general and key population groups for each country in the European Union, European Economic Area and the United Kingdom (EU\/EEA\/UK), including where data are currently unavailable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We combined data from a 2018 systematic review (updated in 2021), data gathered directly by the European Centre for Disease Control (ECDC) from EU\/EEA countries and the UK and further country-level data. We included data on adults from the general population, pregnant women, first time blood donors (FTBD), men who have sex with men (MSM), prisoners, people who inject drugs (PWID), and migrants from 2001 to 2021, with three exceptions made for pre-2001 estimates. Finite Mixture Models (FMM) and Beta regression were used to predict country and population group HBsAg prevalence. A separate multiplier method was used to estimate HBsAg prevalence among the migrant populations within each country, due to biases in the data available.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 595 included studies from 31 countries (N\u2009=\u200941,955,969 people): 66 were among the general population (mean prevalence (<jats:inline-formula><jats:tex-math>$$\\stackrel{-}{p}$$<\/jats:tex-math><\/jats:inline-formula>) 1.3% [range: 0.0-7.6%]), 52 among pregnant women (<jats:inline-formula><jats:tex-math>$$\\stackrel{-}{p}=$$<\/jats:tex-math><\/jats:inline-formula>1.1% [0.1\u20135.3%]), 315 among FTBD (<jats:inline-formula><jats:tex-math>$$\\stackrel{-}{p}=$$<\/jats:tex-math><\/jats:inline-formula>0.3% [0.0-6.2%]), 20 among MSM (<jats:inline-formula><jats:tex-math>$$\\stackrel{-}{p}=$$<\/jats:tex-math><\/jats:inline-formula>1.7% [0.0-11.2%]), 34 among PWID (<jats:inline-formula><jats:tex-math>$$\\stackrel{-}{p}=$$<\/jats:tex-math><\/jats:inline-formula>3.9% [0.0-16.9%]), 24 among prisoners (<jats:inline-formula><jats:tex-math>$$\\stackrel{-}{p}=$$<\/jats:tex-math><\/jats:inline-formula>2.9% [0.0-10.7%]), and 84 among migrants (<jats:inline-formula><jats:tex-math>$$\\stackrel{-}{p}=$$<\/jats:tex-math><\/jats:inline-formula>7.0% [0.2\u201337.3%]). The FMM grouped countries into 3 classes. We estimated HBsAg prevalence among the general population to be &lt;\u20091% in 24\/31 countries, although it was higher in 7 Eastern\/Southern European countries. HBsAg prevalence among each population group was higher in most Eastern\/Southern European than Western\/Northern European countries, whilst prevalence among PWID and prisoners was estimated at &gt;\u20091% for most countries. Portugal had the highest estimated prevalence of HBsAg among migrants (5.0%), with the other highest prevalences mostly seen in Southern Europe.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We estimated HBV prevalence for each population group within each EU\/EAA country and the UK, with general population HBV prevalence to be &lt;\u20091% in most countries. Further evidence is required on the HBsAg prevalence of high-risk populations for future evidence synthesis.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12879-023-08433-3","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T09:02:29Z","timestamp":1688979749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Estimating hepatitis B virus prevalence among key population groups for European Union and European Economic Area countries and the United Kingdom: a modelling study"],"prefix":"10.1186","volume":"23","author":[{"given":"Adam","family":"Trickey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Bivegete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Duffell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"McNaughton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Nerlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine G.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Brooks-Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"8433_CR1","volume-title":"Hepatitis B Fact sheet","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Hepatitis B Fact sheet. Geneva, Switzerland: World Health Organization; 2022."},{"key":"8433_CR2","unstructured":"World Health Organization. Combating hepatitis B and C to reach elimination by 2030. 2016."},{"key":"8433_CR3","volume-title":"Monitoring of responses to the hepatitis B and C epidemics in EU\/EEA countries \u2013 2020 data","author":"European Centre for Disease Prevention and Control","year":"2022","unstructured":"European Centre for Disease Prevention and Control. Monitoring of responses to the hepatitis B and C epidemics in EU\/EEA countries \u2013 2020 data. Stockholm, Sweden: European Centre for Disease Prevention and Control; 2022."},{"issue":"7","key":"8433_CR4","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1017\/S0950268808001672","volume":"137","author":"A Nardone","year":"2009","unstructured":"Nardone A, Anastassopoulou CG, Theeten H, Kriz B, Davidkin I, Thierfelder W, et al. A comparison of hepatitis B seroepidemiology in ten european countries. Epidemiol Infect. 2009;137(7):961\u20139.","journal-title":"Epidemiol Infect"},{"issue":"30","key":"8433_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2807\/1560-7917.ES.2019.24.30.1800614","volume":"24","author":"LMK Mason","year":"2019","unstructured":"Mason LMK, Duffell E, Veldhuijzen IK, Petriti U, Bunge EM, Tavoschi L. Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU\/EEA: a systematic review. Eurosurveillance. 2019;24(30):5\u201320.","journal-title":"Eurosurveillance"},{"key":"8433_CR6","doi-asserted-by":"crossref","unstructured":"Falla AM, Hofstraat SHI, Duffell E, Hahne SJM, Tavoschi L, Veldhuijzen IK. Hepatitis B\/C in the countries of the EU\/EEA: a systematic review of the prevalence among at-risk groups. Bmc Infect Dis. 2018;18.","DOI":"10.1186\/s12879-018-2988-x"},{"issue":"4","key":"8433_CR7","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/eurpub\/cks067","volume":"23","author":"JJ Chu","year":"2013","unstructured":"Chu JJ, Wormann T, Popp J, Patzelt G, Akmatov MK, Kramer A, et al. Changing epidemiology of Hepatitis B and migration-a comparison of six Northern and North-Western european countries. Eur J Public Health. 2013;23(4):642\u20137.","journal-title":"Eur J Public Health"},{"key":"8433_CR8","unstructured":"European Centre for Disease Prevention and Control. Monitoring the responses to hepatitis B and C epidemics in the EU\/EEA Member States. 2019."},{"key":"8433_CR9","unstructured":"European Centre for Disease Prevention and Control. Systematic review on hepatitis B and C prevalence in the EU\/EEA. 2016."},{"key":"8433_CR10","unstructured":"European Centre for Disease Prevention and Control. Hepatitis B - prevalence database 2021 [Available from: https:\/\/www.ecdc.europa.eu\/en\/all-topics-z\/hepatitis-b\/tools\/hepatitis-b-prevalence-database."},{"key":"8433_CR11","doi-asserted-by":"crossref","unstructured":"Bivegete S, Trickey A, Thornton Z, Scanlan B, McNaughton AL, Lim AG et al. Estimates of chronic hepatitis B virus infection among general population and key risk groups in EU\/EEA countries: a systematic review. Eurosurveillance. 2023.","DOI":"10.2807\/1560-7917.ES.2023.28.30.2200738"},{"key":"8433_CR12","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Elimination barometer on viral hepatitis among people who inject drugs in Europe. European Monitoring Centre for Drugs and Drug Addiction; 2021."},{"key":"8433_CR13","unstructured":"World Health Organization. Hepatitis B (HepB3) immunization coverage among 1-year-olds (%). 2021."},{"key":"8433_CR14","unstructured":"European Centre for Disease Prevention and Control. Epidemiological assessment of hepatitis B and C among migrants in the EU\/EEA. 2016."},{"key":"8433_CR15","unstructured":"World Bank. Gross Domestic Product per capita (current US$). 2019."},{"key":"8433_CR16","unstructured":"The World Factbook. Country comparisons - Median age 2020 [Available from: https:\/\/www.cia.gov\/the-world-factbook\/field\/median-age\/country-comparison."},{"key":"8433_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-statistics-031017-100325","volume":"6","author":"GJ McLachlan","year":"2019","unstructured":"McLachlan GJ, Lee SX, Rathnayake SI. Finite Mixture Models. Annu Rev Stat Appl. 2019;6:355\u201378.","journal-title":"Annu Rev Stat Appl"},{"key":"8433_CR18","unstructured":"Akaike H, editor Information theory and an extension of the maximum likelihood principle. 2nd international symposium on information theory; 1973; Tsahkadsor. Armenia, USSR: Akad\u00e9miai Kiad&#243."},{"key":"8433_CR19","unstructured":"Institute for Health Metrics and Evaluation (IHME). Country data dashboards 2019 [Available from: https:\/\/www.globalhep.org\/country-data-dashboards."},{"issue":"6","key":"8433_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","volume":"3","author":"C Polaris Observatory","year":"2018","unstructured":"Polaris Observatory C. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383\u2013403.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10003","key":"8433_CR21","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546\u201355.","journal-title":"Lancet"},{"key":"8433_CR22","doi-asserted-by":"crossref","unstructured":"Ahmad AA, Falla AM, Duffell E, Noori T, Bechini A, Reintjes R et al. Estimating the scale of chronic hepatitis B virus infection among migrants in EU\/EEA countries. Bmc Infect Dis. 2018;18.","DOI":"10.1186\/s12879-017-2921-8"},{"key":"8433_CR23","unstructured":"Eurostat. Population on 1 January by age group, sex and country of birth. 2019 [Available from: https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/migr_pop3ctb\/default\/table?lang=en."},{"key":"8433_CR24","unstructured":"European Statistical Systems (ESS). EU 2011 - Housing and Population Census 2011 [Available from: https:\/\/ec.europa.eu\/CensusHub2\/."},{"key":"8433_CR25","unstructured":"World Health Organization. Global Hepatitis Report 2017. Geneva; 2017."},{"issue":"12","key":"8433_CR26","doi-asserted-by":"publisher","first-page":"E1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):E1192\u2013E207.","journal-title":"Lancet Glob Health"},{"issue":"10049","key":"8433_CR27","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S0140-6736(16)30466-4","volume":"388","author":"K Dolan","year":"2016","unstructured":"Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388(10049):1089\u2013102.","journal-title":"Lancet"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08433-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08433-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08433-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T19:49:47Z","timestamp":1702756187000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08433-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8433"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08433-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,10]]},"assertion":[{"value":"28 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PV and JGW reports research grants from Gilead unrelated to this work. All other authors do not have competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"457"}}